Palvella Therapeutics (PVLA) Competitors $24.01 -0.27 (-1.11%) As of 09:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA vs. ARDX, SNDX, AMPH, AUPH, ADPT, BGM, IOVA, WVE, ETNB, and NRIXShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Ardelyx (ARDX), Syndax Pharmaceuticals (SNDX), Amphastar Pharmaceuticals (AMPH), Aurinia Pharmaceuticals (AUPH), Adaptive Biotechnologies (ADPT), Qilian International Holding Group (BGM), Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), 89bio (ETNB), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Palvella Therapeutics vs. Ardelyx Syndax Pharmaceuticals Amphastar Pharmaceuticals Aurinia Pharmaceuticals Adaptive Biotechnologies Qilian International Holding Group Iovance Biotherapeutics Wave Life Sciences 89bio Nurix Therapeutics Palvella Therapeutics (NASDAQ:PVLA) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Which has more risk & volatility, PVLA or ARDX? Palvella Therapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Do institutionals and insiders believe in PVLA or ARDX? 40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by insiders. Comparatively, 5.9% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is PVLA or ARDX more profitable? Palvella Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -80.93% -59.55% Ardelyx -11.73%-24.87%-10.51% Do analysts rate PVLA or ARDX? Palvella Therapeutics presently has a consensus price target of $44.43, indicating a potential upside of 85.04%. Ardelyx has a consensus price target of $10.61, indicating a potential upside of 89.65%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Ardelyx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, PVLA or ARDX? Palvella Therapeutics has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M6.18-$24.54M-$12.10-1.98Ardelyx$333.62M4.00-$39.14M-$0.16-34.97 Does the MarketBeat Community prefer PVLA or ARDX? Ardelyx received 523 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 67.46% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformPalvella TherapeuticsOutperform Votes14100.00% Underperform VotesNo VotesArdelyxOutperform Votes53767.46% Underperform Votes25932.54% Does the media refer more to PVLA or ARDX? In the previous week, Ardelyx had 4 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for Ardelyx and 6 mentions for Palvella Therapeutics. Ardelyx's average media sentiment score of 1.06 beat Palvella Therapeutics' score of 0.71 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryArdelyx beats Palvella Therapeutics on 11 of the 19 factors compared between the two stocks. Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$264.57M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-1.987.3222.5518.49Price / Sales6.18239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book1.116.436.694.25Net Income-$24.54M$143.21M$3.22B$248.31M7 Day Performance-5.73%1.24%1.11%1.12%1 Month Performance1.78%6.09%3.59%3.68%1 Year PerformanceN/A-3.34%15.65%5.19% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics3.4225 of 5 stars$24.01-1.1%$44.43+85.0%N/A$264.57M$42.81M-1.98N/AAnalyst ForecastARDXArdelyx4.5603 of 5 stars$4.85+0.8%$10.61+118.8%-13.9%$1.16B$333.62M-30.3190Positive NewsSNDXSyndax Pharmaceuticals3.6507 of 5 stars$13.02+0.7%$36.20+178.1%-33.0%$1.12B$23.68M-3.59110Upcoming EarningsPositive NewsAMPHAmphastar Pharmaceuticals4.4978 of 5 stars$23.56-1.5%$43.50+84.6%-40.8%$1.12B$731.97M7.851,620Upcoming EarningsPositive NewsAUPHAurinia Pharmaceuticals2.6458 of 5 stars$8.09+2.5%$11.50+42.2%+61.9%$1.11B$235.13M-53.93300ADPTAdaptive Biotechnologies4.1445 of 5 stars$7.38+5.3%$9.40+27.4%+180.9%$1.10B$178.96M-6.77790News CoveragePositive NewsGap DownBGMQilian International Holding GroupN/A$10.94-4.8%N/AN/A$1.06B$25.10M0.00298IOVAIovance Biotherapeutics4.5644 of 5 stars$3.19-0.6%$18.22+471.2%-69.5%$1.05B$164.07M-2.14500Upcoming EarningsPositive NewsGap DownWVEWave Life Sciences4.3104 of 5 stars$6.79+3.5%$22.18+226.7%+56.6%$1.04B$108.30M-6.12240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageETNB89bio2.7852 of 5 stars$6.62+1.1%$27.25+311.6%-5.8%$966.41MN/A-2.2740Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsNRIXNurix Therapeutics1.9275 of 5 stars$11.61+1.3%$30.44+162.2%-4.1%$885.10M$56.42M-4.02300Analyst ForecastPositive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies ARDX Competitors SNDX Competitors AMPH Competitors AUPH Competitors ADPT Competitors BGM Competitors IOVA Competitors WVE Competitors ETNB Competitors NRIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PVLA Stock Free PVLA Stock Alerts